Competition in long-acting schizophrenia injections between Otsuka and Janssen

When it comes to treating schizophrenia, competition among long-acting injections(LAIs) is about to be intensified.

This is because a series of new drug launches are expected for schizophrenia patients who are having difficulties in constant management of the disease.

According to the industry concerned on the 29^th, the Ministry of Health and Welfare recently registered schizophrenia therap...